MRI预测三阴性乳腺癌新辅助化疗联合免疫治疗病理反应的表现
本研究为回顾性单中心研究,纳入2021—2024年接受新辅助化疗或新辅助化疗联合免疫治疗后手术的三阴性乳腺癌患者111例。所有患者均行治疗前与术前MRI,以RCB-0定义为病理完全缓解。结果显示联合免疫治疗组MRI预测病理完全缓解的敏感度、准确率和AUC均高于单纯化疗组。
要点
- 联合免疫治疗组术前MRI无异常强化时,病理完全缓解概率更高。
- MRI在联合免疫治疗组预测病理完全缓解的敏感度达94.3%。
- 联合免疫治疗组MRI无异常强化比例及病理完全缓解率均显著高于单纯化疗组。
核心结论
- MRI对接受新辅助化疗联合免疫治疗的三阴性乳腺癌患者预测病理完全缓解具有良好的诊断效能。
研究设计与样本
- 回顾性单中心研究,纳入2021—2024年接受新辅助化疗或新辅助化疗联合免疫治疗后手术的女性三阴性乳腺癌患者111例。
- 所有患者均行两次MRI检查:治疗前一次和治疗后术前一次。
- 病理反应采用Residual Cancer Burden指数评估,以RCB-0定义为病理完全缓解。
关键影像表现/征象
- 影像学完全缓解定义为术前MRI未见异常强化。
- 联合免疫治疗组影像学完全缓解率为75%,单纯化疗组为44.1%。
诊断标准与关键数值
- 以病理完全缓解为金标准,联合免疫治疗组MRI敏感度为94.3%,单纯化疗组为67.9%。
- 联合免疫治疗组MRI准确率为84.6%,单纯化疗组为72.8%。
- 联合免疫治疗组MRI的AUC为0.736,单纯化疗组为0.602。
- 联合免疫治疗组病理完全缓解率为67.3%,单纯化疗组为47.5%,P=0.025。
- 联合免疫治疗组影像学完全缓解率高于单纯化疗组,P<0.001。
临床应用与阅片要点
- 对接受新辅助化疗联合免疫治疗的三阴性乳腺癌患者,可将术前MRI无异常强化作为预测病理完全缓解的重要参考。
- MRI可作为非侵入性工具辅助治疗个体化和潜在手术降级决策。
- 阅片时仍需注意MRI对病理完全缓解的预测并非完全准确,存在假阴性和假阳性可能。
局限性
- 本研究为回顾性单中心设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Triple-negative breast cancer (TNBC) is an aggressive subtype of invasive breast carcinoma with limited treatment options. Neoadjuvant chemotherapy (NAC) is a standard approach, allowing less extensive surgeries and enabling in vivo assessment of treatment response. MRI plays a key role in evaluating this response. Recently, the addition of immune checkpoint inhibitors has transformed the treatment landscape. This study aims to compare the diagnostic performance of MRI in predicting the pathological response in patients with invasive TNBC undergoing NAC with and without immunotherapy.
MATERIALS AND METHODS: This retrospective single-center study included female patients with TNBC who underwent NAC or NACI followed by surgery between 2021 and 2024. All patients underwent two MRIs: one before treatment (pretreatment) and one after treatment (preoperative). Radiologic complete response (rCR) was defined as the absence of abnormal enhancement at preoperative MRI. Pathological response was assessed by the Residual Cancer Burden (RCB) index, with pCR defined as RCB-0. MRI performance was calculated using pathological response as the gold standard.
RESULTS: A total of 111 patients were included: 59 in the NAC group and 52 in the NACI group. The NACI group showed higher rates of rCR (75% vs. 44.1%; p < 0.001) and pCR (67.3% vs. 47.5%; p = 0.025). MRI demonstrated superior sensitivity (94.3% vs. 67.9%), accuracy (84.6% vs. 72.8%), and AUC (0.736 vs. 0.602) in the NACI group.
CONCLUSION: MRI demonstrated good diagnostic performance in predicting pCR in patients with TNBC treated with NAC associated with immunotherapy.
KEY POINTS: Question Triple-negative breast cancer (TNBC) is an aggressive subtype with limited treatment options. NAC is standard, but the addition of immunotherapy has shown improved outcomes in early TNBC. Findings MRI demonstrated higher sensitivity (94.3% vs. 67.9%) and accuracy (84.6% vs. 72.8%) in predicting pCR in patients with TNBC treated with NAC associated with immunotherapy, with an AUC of 0.736 compared to 0.602. Clinical relevance In patients with TNBC treated with neoadjuvant chemotherapy and immunotherapy, MRI demonstrates improved accuracy in predicting pathological complete response, supporting its use as a noninvasive tool to guide treatment personalization and potential surgical de-escalation.
引用
- Damião, de Melo, Carneiro, et al. Diagnostic performance of MRI in predicting pathological response in patients with triple-negative breast carcinomas undergoing neoadjuvant chemotherapy and immunotherapy. Eur Radiol. 2026. PMID: 41498827. doi:10.1007/s00330-025-12270-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。